Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | S100A4 | P26447 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13924972 | 0.87 | NR1H2 (0.41) | STAT3ALDH1A1S100A4MEN1KMT2A | |
| SCHEMBL6995078 | 0.84 | S100A4 (0.51) | ALDH1A1S100A4MEN1KMT2AMAOA | |
| SCHEMBL10037461 | 0.83 | MAOA (0.56) | STAT3ALDH1A1MEN1KMT2AMAOA | |
| SCHEMBL20187634 | 0.83 | ALDH1A1 (0.54) | STAT3ALDH1A1MEN1KMT2AMAOA | |
| SCHEMBL18384539 | 0.82 | MAPK14 (0.48) | STAT3ALDH1A1MAOAMAPTSMN1; SMN2 | |
| SCHEMBL18384601 | 0.82 | MAPK14 (0.48) | STAT3ALDH1A1MAOAMAPTSMN1; SMN2 | |
| SCHEMBL18384613 | 0.81 | GAA (0.49) | S100A4MEN1KMT2ACDC25BMAPK14 | |
| SCHEMBL18384503 | 0.81 | TDP2 (0.45) | S100A4MEN1KMT2ACDC25BMAPK14 | |
| SCHEMBL6992698 | 0.80 | CES1 (0.46) | STAT3ALDH1A1MAPTMAPK14HPGD | |
| SCHEMBL6001534 | 0.80 | MAPK14 (0.48) | ALDH1A1MEN1KMT2AMAOAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1093456-B1 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2003-12-17 | — | — | EP | claimed |
| EP-1093456-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-04-25 | — | — | EP | claimed |
| US-6174913-B1 | TREATING TUMOR BY ADMINISTERING COMPOUNDS E.G.:2-ACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE; 2,7-DIACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-01-16 | — | — | US | claimed |
| WO-1999062909-A9 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2000-04-27 | — | — | WO | claimed |
| WO-1999062909-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-12-09 | — | — | WO | claimed |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-1551392-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026253-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1093456-B1 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2003-12-17 | — | — | EP | disclosed |
| US-6337346-B1 | BENZODITHIOPHENE DERIVATIVES | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2002-01-08 | — | — | US | disclosed |
| EP-1093456-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2001-04-25 | — | — | EP | disclosed |
| US-6174913-B1 | TREATING TUMOR BY ADMINISTERING COMPOUNDS E.G.:2-ACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE; 2,7-DIACETYL-NAPHTHO(2,3-B)THIOPHENE-4,9-DIONE | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2001-01-16 | — | — | US | disclosed |
| WO-1999062909-A9 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIV NORTH CAROLINA (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1999062909-A2 | NAPHTHO- AND DIHYDROBENZO-THIOPHENE DERIVATIVES AS CYTOTOXIC ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | STAT3 1/4885ALDH1A1 677/4885S100A4 3330/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | STAT3 1/4885ALDH1A1 545/4885S100A4 3540/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | STAT3 1/4885ALDH1A1 630/4885S100A4 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.